RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone

Journal of Bone and Mineral Research

Volumn 21, Issue 9, 2006, Pages 1339-1349

  Atkins, Gerald J ^a   Kostakis, Panagiota ^a,b   Vincent, Cristina ^a   Farrugia, Amanda N ^b   Houchins, Jeffrey P ^c   Findlay, David M ^a   Evdokiou, Andreas ^a   Zannettino, Andrew C W ^b,d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b HANSON INSTITUTE   (Australia)

^c R and D Systems Inc   (United States)

^d INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

Giant cell tumor; Hematopoietic cells; Monoclonal antibodies; RANK

Indexed keywords

CD14 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CELL SURFACE MARKER; COLONY STIMULATING FACTOR 1; GLYCOPHORIN A; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN RANK; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROID PRECURSOR CELL; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL BLOOD STEM CELL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD14; ANTIGENS, SURFACE; B-LYMPHOCYTES; BONE MARROW CELLS; CARRIER PROTEINS; CELL LINEAGE; GIANT CELL TUMOR OF BONE; HEMATOPOIETIC STEM CELLS; HUMANS; MEMBRANE GLYCOPROTEINS; MONOCYTES; OSTEOCLASTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECOMBINANT PROTEINS;

EID: 33748068083     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.060604     Document Type: Article

References (42)

1. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179.
2. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ 1999 Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:3540-3545.
3. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ 2000 RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97:1566-1571.
4. Boyle WJ, Simonet WS, Lacey DL 2003 Osteoclast differentiation and activation. Nature 423:337-342.
5. Faccio R, Takeshita S, Zallone A, Ross FP, Teitelbaum SL 2003 c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin Invest 111:749-758.
6. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL 2000 The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2-12.
7. Menaa C, Kurihara N, Roodman GD 2000 CFU-GM-derived cells form osteoclasts at a very high efficiency. Biochem Biophys Res Commun 267:943-946.
8. Massey HM, Flanagan AM 1999 Human osteoclasts derive from CD14-positive monocytes. Br J Haematol 106:167-170.
9. Hayase Y, Muguruma Y, Lee MY 1997 Osteoclast development from hematopoietic stem cells: Apparent divergence of the osteoclast lineage prior to macrophage commitment. Exp Hematol 25:19-25.
10. Miyamoto T, Ohneda O, Arai F, Iwamoto K, Okada S, Takagi K, Anderson DM, Suda T 2001 Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 98:2544-2554.
11. Fujikawa Y, Quinn JM, Sabokbar A, McGee JO, Athanasou NA 1996 The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 137:4058-4060.
12. Fuller K, Chambers TJ 1998 Parathyroid hormone induces bone resorption in human peripheral blood mononuclear cells. Int J Exp Pathol 79:223-233.
13. Shalhoub V, Elliott G, Chiu L, Manoukian R, Kelley M, Hawkins N, Davy E, Shimamoto G, Beck J, Kaufman SA, Van G, Scully S, Qi M, Grisanti M, Dunstan C, Boyle WJ, Lacey DL 2000 Characterization of osteoclast precursors in human blood. Br J Haematol 111:501-512.
14. Goldring SR, Roelke MS, Petrison KK, Bhan AK 1987 Human giant cell tumors of bone identification and characterization of cell types. J Clin Invest 79:483-491.
15. James IE, Dodds RA, Lee-Rykaczewski E, Eichman CF, Connor JR, Hart TK, Maleeff BE, Lackman RD, Gowen M 1996 Purification and characterization of fully functional human osteoclast precursors. J Bone Miner Res 11:1608-1618.
16. Zannettino AC, Buhring HJ, Niutta S, Watt SM, Benton MA, Simmons PJ 1998 The sialomucin CD164 (MGC-24v) is an adhesive glycoprotein expressed by human hematopoietic progenitors and bone marrow stromal cells that serves as a potent negative regulator of hematopoiesis. Blood 92:2613-2628.
17. Harlow E, Lane D 1988 Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, USA.
18. Kohler G, Milstein C 1975 Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497.
19. Atkins GJ, Bouralexis S, Haynes DR, Graves SE, Geary SM, Evdokiou A, Zannettino AC, Hay S, Findlay DM 2001 Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone 28:370-377.
20. Atkins GJ, Kostakis P, Welldon KJ, Vincent C, Findlay DM, Zannettino AC 2005 Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. J Cell Physiol 203:573-582.
21. Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P, Findlay DM, Bardy P, Zannettino AC 2003 Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63:5438-5445.
22. Atkins GJ, Haynes DR, Geary SM, Loric M, Crotti TN, Findlay DM 2000 Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation. Bone 26:653-661.
23. Atkins GJ, Haynes DR, Graves SE, Evdokiou A, Hay S, Bouralexis S, Findlay DM 2000 Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 15:640-649.
24. Cole SR, Ashman LK, Ey PL 1987 Biotinylation: An alternative to radioiodination for the identification of cell surface antigens in immunoprecipitates. Mol Immunol 24:699-705.
25. Zannettino AC, Rayner JR, Ashman LK, Gonda TJ, Simmons PJ 1996 A powerful new technique for isolating genes encoding cell surface antigens using retroviral expression cloning. J Immunol 156:611-620.
26. Ikeda T, Kasai M, Utsuyama M, Hirokawa K 2001 Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 142:1419-1426.
27. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
28. Kim HH, Lee DE, Shin JN, Lee YS, Jeon YM, Chung CH, Ni J, Kwon BS, Lee ZH 1999 Receptor activator of NF-kappaB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase. FEBS Lett 443:297-302.
29. Roux S, Meignin V, Quillard J, Meduri G, Guiochon-Mantel A, Fermand JP, Milgrom E, Mariette X 2002 RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol 117:86-92.
30. Mosheimer BA, Kaneider NC, Feistritzer C, Sturn DH, Wiedermann CJ 2004 Expression and function of RANK in human monocyte chemotaxis. Arthritis Rheum 50:2309-2316.
31. Walsh MC, Choi Y 2003 Biology of the TRANCE axis. Cytokine Growth Factor Rev 14:251-263.
32. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J 1999 RANK is essential for osteoclast and lymph node development. Genes Dev 13:2412-2424.
33. Jacquin C, Lee SK, Lorenzo JA, Aguilla HL 2005 RANK deficiency in the hematopoietic compartment alters the development of osteoclasts but not other hematopoietic lineages. J Bone Miner Res 20:Suppl 1;S145.
34. Manabe N, Kawaguchi H, Chikuda H, Miyaura C, Inada M, Nagai R, Nabeshima Y, Nakamura K, Sinclair AM, Scheuermann RH, Kuro-o M 2001 Connection between B lymphocyte and osteoclast differentiation pathways. J Immunol 167:2625-2631.
35. Blin-Wakkach C, Wakkach A, Rochet N, Carle GF 2004 Characterization of a novel bipotent hematopoietic progenitor population in normal and osteopetrotic mice. J Bone Miner Res 19:1137-1143.
36. Xing L, Schwarz EM, Boyce BF 2005 Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev 208:19-29.
37. Horowitz MC, Bothwell AL, Hesslein DG, Pflugh DL, Schatz DG 2005 B cells and osteoblast and osteoclast development. Immunol Rev 208:141-153.
38. Moretta A, Marcenaro E, Sivori S, Chiesa MD, Vitale M, Moretta L 2005 Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol 36:668-675.
39. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323.
40. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T 1999 Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 190:1741-1754.
41. Dewar AL, Farrugia AN, Condina MR, To LB, Hughes TP, Vernon-Roberts B, Zannettino AC 2006 Imatinib as a potential anti-resorptive therapy for bone disease. Blood 107:4334-4337.
42. Seshasayee D, Wang H, Lee WP, Gribling P, Ross J, Van Bruggen N, Carano R, Grewal IS 2004 A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. J Biol Chem 279:30202-30209.